|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||211.7900 - 213.3600|
|52 Week Range||166.8900 - 213.3600|
|Beta (3Y Monthly)||0.89|
|PE Ratio (TTM)||0.00|
|Earnings Date||Jan 28, 2019 - Feb 1, 2019|
|Forward Dividend & Yield||2.00 (0.97%)|
|1y Target Est||208.31|
Larry Merlo has learned a few things during nearly eight years as CEO of one of the nation's biggest drugstore chains — including that you shouldn't ever stop learning. CVS Health Corp. is polishing off a $69-billion acquisition of the health insurer Aetna. The company, which also manages pharmacy benefits, is focusing more on providing in-store health care services and telemedicine, as retailers face pressing competition for product sales from the online giant Amazon.com.
CVS Health CEO Larry Merlo wants customers to think about more than prescriptions and shampoo when they visit his company's drugstores. CVS has largely finished its $69 billion acquisition of the insurer Aetna, part of the company's broader effort to expand its health care offerings. Merlo spoke recently with The Associated Press.
CVS Health Corp (CVS.N) defended on Friday an agreement with the U.S. Justice Department which allowed it to purchase health insurer Aetna for $69 billion, a settlement that a federal judge is still assessing. The Justice Department approved the merger of CVS, a U.S. pharmacy chain and benefits manager, and Aetna in October on condition that Aetna sell its Medicare prescription drug plan business to WellCare Health Plans Inc (WCG.N). Now, the Justice Department and companies have found themselves in the unusual position of defending their antitrust settlement to a skeptical federal judge.
The Justice Department approved the merger of CVS, a U.S. pharmacy chain and benefits manager, and Aetna in October on condition that Aetna sell its Medicare prescription drug plan business to WellCare Health Plans Inc . Now, the Justice Department and companies have found themselves in the unusual position of defending their antitrust settlement to a skeptical federal judge. In its brief, filed on Friday, CVS said that the deal had been extensively reviewed and urged the judge to allow the companies to continue integrating while he examines the settlement reached with the government.
Goldman analyst Robert Jones said he doesn't think Walgreens' numerous partnerships with other companies will help offset declines in its core retail pharmacy business. He downgraded Walgreens to "sell" from "hold" Friday.
Goldman analyst Robert Jones said he doesn't think Walgreens' numerous partnerships with other companies will help offset declines in its core retail pharmacy business. He downgraded Walgreens to "sell" ...
SINGAPORE (AP) — Asian markets tumbled on Friday after China reported weaker-than-expected economic data, stirring up worries about the state of the world's second largest economy.
Stocks that moved substantially or traded heavily Thursday: CVS Health Corp., down $1.13 to $73.37 The New York Post reported that a judge might bar CVS from integrating its business with health insurer ...
The Dow Jones Industrial Average rose Thursday as Wall Street expressed optimism over U.S. and China trade talks. said Thursday it would invest $1 billion to build a new campus in Austin, Texas. Stocks traded mixed on Thursday, Dec. 13, as Wall Street monitored trade developments between the U.S. and China, the world's two largest economies.
U.S. stock futures were mixed on Thursday, Dec. 13, and shares in Asia closed higher as trade tensions eased between the U.S. and China, the world's two largest economies. Wall Street finished higher on Wednesday, Dec. 12, as investors cheered progress in U.S.-China trade talks and after a report said China was planning a new program that promised greater access for foreign companies. The Wall Street Journal reported Wednesday that China was drafting a replacement for Made in China 2025 - President Xi's blueprint to make the country a leader in high-tech industries - which would play down China's bid to dominate manufacturing and be more open to participation by foreign companies.
CVS Health acquired health insurance giant Aetna for about $70 billion. CVS has bought other pharmacies to build its footrprint, as well as pharmacy benefit manager Caremark and walk-in health clinic MinuteClinic. It's buying a health insurer to prove it.
To start 2018, many on Wall Street were predicting a great year for stocks, as Donald Trump's tax plan was expected to produce elevated mergers and acquisitions activity. The deal activity has certainly been a part of the 2018 story, but the trend could slow down in 2019, said analysts from Goldman Sachs. Deal announcements are expected to increase 20% year over year in 2018, according to a note from Goldman that was released Tuesday.
Walgreens Boots Alliance Inc. has teamed up with FedEx Corp. to launch a nationwide next-day prescription home-delivery service as the drugstore chain works to stave off competition from Amazon.com Inc. and other rivals. Under the delivery service called Walgreens Express, patients enrolled in text alerts will receive text notification when qualifying prescriptions are ready, Walgreens said Thursday. For a $4.99 fee, patients can have their prescriptions delivered by FedEx to their home as early as the next day.
Walgreens is joining rival drugstore chain CVS Health in expanding home deliveries for prescriptions nationwide, as stores continue adjusting to a retail world made more consumer-friendly by online competition. Walgreens said Thursday it will partner with FedEx to deliver prescriptions as soon as the next day for a $4.99 fee, and it also is providing same-day deliveries in several cities including New York, Chicago and Dallas. Walgreens and FedEx Corp. began a partnership last year where the drugstore chain started offering package drop-off and pick-up services at several thousand stores.
The company announced a new pricing model for its pharmacy benefit management services Wednesday morning. The White House has been an active critic of PBMs, which negotiate drug discounts on behalf of employers and health plans, arguing that they have distorted the drug-pricing system. Drugmakers pay rebates than can amount to more than 50 percent of a drug’s sticker price to secure favorable coverage on PBM drug lists, and critics contend that firms like CVS keep an excessive slice of those undisclosed payments.
"There's a way to get all of that digitally on your phone," along with the coupons and extra bucks rewards, CVS CEO Larry Merlo tells CNBC's Bertha Coombs.
The "guaranteed net cost" option could also deflect growing criticism that pharmacy benefit managers (PBMs) reap gains off the widening gap between pharmaceutical list prices and their lower net cost after hefty rebates paid by drugmakers to secure coverage and access to their products. President Donald Trump, who has promised lower prescription drug costs for U.S. consumers, earlier this year singled out industry "middlemen", such as PBMs and insurers, and the common practice of drugmakers offering rebates to them.